EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 33 / No 10 (Octobre 2017) Med Sci (Paris), 33 10 (2017) 891-897 References
Free Access
Issue
Med Sci (Paris)
Volume 33, Number 10, Octobre 2017
Page(s) 891 - 897
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20173310022
Published online 10 October 2017
  1. PREVAIL II writing group; Multi-national PREVAIL II study team, Davey RT Jr, Dodd L, Proschan MA, et al. A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med 2016; 375 : 1448–1456. [Google Scholar]
  2. Fassin D. Santé globale, un nouveau concept ? Quelques enseignements de l’épidémie à virus Ébola. Med Sci (Paris) 2015 ; 31 : 463–464. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  3. Briand S, Bertherat E, Cox P, et al. The international Ebola emergency. New Engl J Med 2014 ; 371 : 1180–1183. [CrossRef] [Google Scholar]
  4. Krech R, Kieny MP. The 2014 Ebola outbreak: ethical use of unregistered interventions. Bull World Health Organ 2014 ; 92 : 622. [CrossRef] [PubMed] [Google Scholar]
  5. Yazdanpanah Y, Arribas JR, Malvy D. Treatment of Ebola virus disease. Intensive Care Med 2015 ; 41 : 115–117. [CrossRef] [PubMed] [Google Scholar]
  6. Zeitlin L, Whaley KJ, Olinger GG, et al. Antibody therapeutics for Ebola virus disease. Curr Opin Virol 2016 ; 17 : 45–49. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  7. Jahrling P, Geisbert T, Geisbert J, et al. Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections. J Infect Dis 1999 ; 179 (suppl 1) : S224–S234. [CrossRef] [PubMed] [Google Scholar]
  8. van Griensven J, Edwards T, de Lamballerie X, et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med 2016 ; 374 : 33–42. [Google Scholar]
  9. Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in non-human primates with ZMapp. Nature 2014 ; 514 : 47–53. [CrossRef] [PubMed] [Google Scholar]
  10. Malvy D. Science in a crisis. Medical countermeasures in Ebola virus disease, 2016: lessons learned and perspectives. Bull Soc Pathol Exot 2016 ; 109 : 262–271. [CrossRef] [PubMed] [Google Scholar]
  11. Dodd LE, Proschan MA, Neuhaus J, et al. Design of a randomized controlled trial for Ebola virus disease medical countermeasures: PREVAIL II, the Ebola MCM Study. J Infect Dis 2016 ; 213 : 1906–1913. [CrossRef] [PubMed] [Google Scholar]
  12. Henao-Restrepo AM, Camacho A, Longini IM, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola ça suffit !). Lancet 2017 ; 389 : 505–518. [CrossRef] [PubMed] [Google Scholar]
  13. Sissoko D, Laouénan C, Folkesson E, et al. Experimental treatment of favipiravir for Ebola virus disease (the JIKI trial): a historically-controlled, single arm proof-of concept trial in Guinea. PLoS Med 2016 ; 13 : e1001967. [Google Scholar]
  14. Duraffour S, Malvy D, Sissoko D. How to treat Ebola virus infections? A lesson from the field. Curr Opin Virol 2017 ; 24 : 9–15. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  15. Dunning J, Sahr F, Rojek A, et al. Experimental treatment of Ebola virus disease with TKM-130803: A single-arm Phase 2 clinical trial. PLoS Med 2016 ; 13 : e1001997. [Google Scholar]
  16. Dunning J, Kennedy SB, Antierens A, et al. Experimental treatment of Ebola virus disease with brincidofovir. PLoS One 2016 ; 11 : e0162199. [CrossRef] [PubMed] [Google Scholar]
  17. Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 2016 ; 531 : 381–385. [CrossRef] [PubMed] [Google Scholar]
  18. Nguyen TH, Guedj J, Anglaret X, et al. Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS Negl Trop Dis 2017 ; 11 : e0005389. [CrossRef] [PubMed] [Google Scholar]
  19. Sissoko D, Duraffour S, Kerber R, et al. Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study. Lancet Glob Health 2017 ; 5 : e80–e88. [Google Scholar]
  20. Ethical issues related to study design for trials on therapeutics for Ebola Virus Disease. 2014. Report of the WHO ethics working group meeting. 20–21 October 2014. Geneva : World health Organization, 2014. http://apps.who.int/iris/bitstream/10665/137509/1/WHO_HIS_KER_GHE_14.2_eng.pdf. [Google Scholar]
  21. Diallo B, Sissoko D, Loman NJ, et al. Resurgence of Ebola virus disease in Guinea linked to a survivor with virus persistence in seminal fluid for more than 500 days. Clin Infect Dis 2016 ; 63 : 1353–1356. [CrossRef] [PubMed] [Google Scholar]
  22. Maehira Y, Kurosaki Y, Saito T, et al. Responding to ever-changing epidemiological dynamics of Ebola virus disease. BMJ Global Health 2016 ; 1 : e000180. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.